Home » Stocks » iTeos Therapeutics

iTeos Therapeutics, Inc. (ITOS)

Stock Price: $27.91 USD -0.39 (-1.38%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 933.17M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 33.43M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $27.91
Previous Close $28.30
Change ($) -0.39
Change (%) -1.38%
Day's Open 28.37
Day's Range 26.20 - 29.00
Day's Volume 230,807
52-Week Range 17.50 - 29.80

More Stats

Market Cap 933.17M
Enterprise Value 785.31M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 33.43M
Float 140,879
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.72
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 147.85M
Net Cash / Share 4.42
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue--
Operating Income-28.05-21.50
Net Income-22.45-18.06
Shares Outstanding0.670.62
Earnings Per Share-39.51-32.63
Operating Cash Flow-23.15-19.10
Capital Expenditures-0.72-0.23
Free Cash Flow-23.87-19.32
Cash & Equivalents19.9922.05
Net Cash / Debt19.9922.05
Assets30.7427.39
Liabilities15.0812.34
Book Value-36.09-10.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name iTeos Therapeutics, Inc.
Country United States
Employees 43
CEO Michel Detheux

Stock Information

Ticker Symbol ITOS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ITOS
IPO Date July 24, 2020

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains. The company was founded in 2011 and is based in Cambridge, Massachusetts with an additional location in Gosselies, Belgium.